Continuous Subcutaneous Apomorphine Infusion (CSAI) Reduces OFF Periods and Extends Periods of GOOD ON Time: Heatmap Analysis of the TOLEDO Study
Objective: Use heatmap analysis to quantify and examine diurnal patterns of OFF and GOOD ON time periods throughout the day, and changes in the number…Efficacy of ND0612 in Patients at Different Stages of Disease Severity: Subgroup-Analyses From a Randomized, Active-Controlled Study in People With Parkinson’s Disease Experiencing Motor Fluctuations
Objective: To evaluate the efficacy of investigational ND0612 in reducing motor fluctuations in patients with Parkinson’s disease (PD) at different stages of disease and/or symptom…Adaptive Deep Brain Stimulation for Parkinson’s Disease in Routine Clinical Care: First Experiences
Objective: To describe the treatment process and outcomes of the first patients with Parkinson’s disease (PD) treated with adaptive DBS (aDBS) within routine clinical care…Safety, Tolerability, and Preliminary Efficacy of NouvNeu001 for the Treatment of Advanced Parkinson’s Disease: A Multi-center, Open Label, Phase 1 Study
Objective: This Phase 1 study aims to evaluate the safety, tolerability, preliminary efficacy, and optimal dose of NouvNeu001 for treating mid to late-stage Parkinson’s disease…The Feedback Loop: Illness Perceptions and Motor Complications in Parkinson’s
Objective: To explore the relationship between motor complications, illness perceptions and cognitive beliefs about symptoms in people with Parkinson's disease (PwP). Background: Around 50% PwP…Antiparkinson Medication Reduces the Probability of the Multiple Step Saccade Pattern During a Memory-Guided Saccade Task
Objective: We wanted to determine how the multiple step saccade pattern responds to antiparkinson medication, as it has been proposed to use this pattern as…VQ-101, a CNS-Penetrant Small Molecule Allosteric Activator of Glucocerebrosidase (GCase), Demonstrates Favorable Tolerability and Sustained Activation of Lysosomal GCase in Individuals with Parkinson’s Disease
Objective: To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of VQ-101 in healthy volunteers (HVs), and individuals with Parkinson’s disease (PD) with and without GBA1…The Effect of Foslevodopa/Foscarbidopa Treatment on Nonmotor Symptom Burden in Advanced Parkinson’s Disease
Objective: To investigate the impact of foslevodopa/foscarbidopa (LDp/CDp) on nonmotor symptoms (NMS) in adults with advanced Parkinson’s disease (aPD). Background: LDp/CDp, a 24-hour per day…Inpatient Multimodal Intensive Care in Moderately Advanced Parkinson’s Disease: Role Of Medication Adjustment In Outcome Measures
Objective: In this study, we wish to determine whether medication changes play a major role in the improvements observed after in-patient multimodal intensive neurorehabilitation and…Opicapone improves end-of-dose neuropsychiatric fluctuations in patients with Parkinson’s disease
Objective: We aim to evaluate the efficacy of Opicapone (OPC) on end-of-dose neuropsychiatric fluctuations, the most frequent and severe non-motor fluctuations (NMF) in Parkinson’s disease (PD) patients [1].…
- « Previous Page
- 1
- …
- 82
- 83
- 84
- 85
- 86
- …
- 436
- Next Page »